Cross-Sector entity
Novavax is most often covered alongside B. Riley Financial, which appears in 3 of these 5 stories. The 17-day window averages about 2.1 stories each week. The busiest single day carried 3. Coverage clusters in market-trends, which accounts for 2 of those 5, with the remainder spread across 2 other categories.
5 verified stories tracked
Last mentioned: 5d ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 40 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Novavax is most often covered alongside B. Riley Financial, which appears in 3 of these 5 stories. The 17-day window averages about 2.1 stories each week. The busiest single day carried 3. Coverage clusters in market-trends, which accounts for 2 of those 5, with the remainder spread across 2 other categories. 0% of these stories carry negative sentiment. The tracked stories average 2.8 original sources each. We currently track 5 Cross-Sector stories that mention Novavax, published between August 4, 2026 and August 20, 2026.
Computed from the 5 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Novavax. Shared-story counts are live from our verified record — not editorial picks.
For finance readers, Aug. 19 was a case study in cross-asset relief: Treasury buyback news pulled the 30-year yield off its highest since 2007, feeding a 0.21% S&P 500 gain, while a more than 137% Moderna surge drove healthcare to a record 2.9% gain. The support for risk appetite masks a hawkish Fed minutes message and an unresolved long-term rate threat to AI-heavy valuations.
Moderna's mRNA cancer therapy readout sent its shares up as much as 177%, driving a 2.9% record gain in the S&P 500 healthcare sector amid easing Treasury yields. The rally lifted peers including Merck, BioNTech and Novavax, but macro rate worries persist.
Source: Sph Media (sg) · Reuters (my)
Wall Street Zen downgraded vaccine maker Novavax to sell, raising alarms in the healthcare sector. The stock traded at $7.41, far below its $13 consensus target, with a negative P/E of -12.78.
In a single day, Wall Street Zen downgraded CME Group to strong sell, and Novavax and SNDL to sell, sending bearish signals across exchanges, biotech, and cannabis. Markets digest the calls amid wide analyst disagreement.
Novavax was slapped with a sell rating by Wall Street Zen, even after beating Q1 revenue estimates by 49%. The downgrade highlights biotech skepticism toward small-cap vaccine players in a shifting market.
Source: dailypolitical.com · tickerreport.com
